Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po


Iskalni niz: "avtor" (Borut Štabuc) .

1 - 10 / 81
Na začetekNa prejšnjo stran123456789Na naslednjo stranNa konec
The urokinase plasminogen activator and its inhibitors PAI-1 nad PAI-2 in primary cutaneous melanoma
Jasmina Markovič Božič, Borut Štabuc, 2003, izvirni znanstveni članek

Povzetek: Background. We investigated the differences in urokinase plasminogen activator(uPA) and its inhibitors type-1 and 2 (PAI-1/2) concentrations in clinically suspected nevi, primary cutaneous melanoma and normal skin and correlations with histopathological prognostic factors of primary melanoma. Patients and methods. Fifty-one patients were enrolled. The tissue concentrations of uPA, PAI 1 and PAI2 were quantified by enzyme-linked immunosorbent assay (ELISA). Results. Mean uPA and PAI-1 concentrations in melanomas were higher than in normal surrounding skin (uPA: 1.08; vs. 0.48 ng/mgp; PAI-1: 14.07 vs. 2.07 ng/mgp; p < 0.001), uPA and PAI-1 concentrationswere higher in melanomas than in nevi, and higher in nevi than in normal surrounding skin (uPA: p > 0.05; PAI-1: p = 0.02). PAI-2 concentration was higher in normal surrounding skin than in nevi and melanomas(p > 0.05). Melanoma uPA, PAI-1 and PAI-2 concentrations correlated significantly with normal skin (r= 0.73, 0.54, 0.38 respectively). PAI 1 was significantly lower in melanomas of Breslow thickness < 0.75 mm, Clark invasion of O+I, without microscopic ulceration, without vascular invasion (p < 0.01) than in melanomas of Breslow thickness > 0.75 mm, Clark invasion > II,with ulceration and vascular invasion. Conclusions. Determination of uPA and PAI-1 can provide significant additional prognostic information for melanoma patients.
Objavljeno v DiRROS: 06.02.2024; Ogledov: 56; Prenosov: 10
.pdf Celotno besedilo (231,89 KB)

Assessment of renal function from creatinine clearance measurement and 131I-hippuran renography in cancer patients before chemotherapy
Borut Štabuc, Tine Hajdinjak, Tomaž Edvard Cizej, 1999, izvirni znanstveni članek

Povzetek: Background. Serum creatinine and endogenous creatinine clearance (CrCl) are widely used measures of renal function before prescribing nephrotoxic chemotherapy. This study compares the precision and bias in glomerular filtration rate (GFR) estimation without the need to collect urine by using Cockcroft-Gault formula on a single serum creatinine concentration (CrCo) and 131I- hippuran clearance (HC) determined from the renographic curves. Patientsand methods. Fourty-seven patients aged between 27 and 73 years were studied. In all patients, we determined serum creatinine concentration, CrCl, CrCo and HC simultaneously before treatment by combined chemotherapy with cisplatin (CDDP) and in 31 patients, before the third cycle. Serum and urine creatinine concentrations were determined with a Hitachi 911, an automated biochemical analyser CrCl was calculated from the urine flow, from the ratio between the serum and urine creatinine concentrations and was standardized forthe body surface area. Serum creatinine was used to estimate CrCo using a Cockcroft and Gault formula. HC was determined from 131I-hippuran uptake by both kidneys, results were compared to our Nuclear Medicine Department normal values with regard to the age of each patient. For the evaluation of results, Pearson's correlation coefficient and t-test with 95 % confidence interval were used. Results. The sensitivity of serum creatinine, CrCo and HC to predict CrCl<78 mL/min/1.73m2 was 41 %, 68% and 46% and specificity was 95%, 71 % and 76% respectively. Value of CoCr for prediction of reduced CrCl (sensitivity) was statistically significantly better than the HC (p=0.03). Value of CoCr fnr prediction of normal CrCl (specificity) was as good as HC (p=0.3). Conclusions. CrCl for the GFR estimation in the patients treated withnephrotoxic chemotherapy cannot be changed by CrCo and/or HC.
Objavljeno v DiRROS: 22.01.2024; Ogledov: 87; Prenosov: 28
.pdf Celotno besedilo (463,87 KB)

Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer
Borut Štabuc, Aleksandra Markovič, Erik Brecelj, Samir Bešlija, Tomaž-Edvard Cizej, 1998, izvirni znanstveni članek

Povzetek: Based on in viro studies that have demonstrated synergy between fluorouracil (5-FU) and leucovorin (LV) as well as between 5-FU and recombinant alpha-2a interferon (IFN) against colon cancer cell lines a phase II study was carried out to evaluate the toxicity and clinical activity of 5-FU modulated with LV and IFN in patients with metastatic colon cancer. Twenty-two chemotherapy naive patients with measurable metastases of colon cancer have been treated with daily doses of 5-FU 600 mg/m2 in 6-hr intravenous infusion, and of LV 20 mg/m2 intravenously and IFN 6 MU subcutaneously, for 5 days every 4 weeks. Median age was 60 years, median PS (ECOG) was 1 (range 0-2). Liver, soft tissue and lung metastases were found in 12, 5 and 8 patients, respectively. Nineteen patients had a single metastatic site, two double, whereas one had more than two metastatic sites. Patients had 2-9 (mean 5) cycles of treatment.Objective response was observed in 7 patients (32%), and stable disease in 7 patients (32%). Overall median survival was 12.5 months, and for responders 14.4 months. Responses were generally short and median time for progression was 5.5 months. The most frequent adverse reactions were flu-like syndrome (50%), nausea/vomiting (36%), diarhoea (13Č), stomatitis (27%) and leucopenia (13%). This regimen of 5-FU with LV and IFN administration does notappear to be superior to previously published shedules of 5-FU with IFN or 5-FU with LV.
Objavljeno v DiRROS: 19.01.2024; Ogledov: 85; Prenosov: 33
.pdf Celotno besedilo (430,62 KB)

Anti-tumor effect of interferon alpha in combination with cisplatin - animal experiments
Borut Štabuc, 1993, ni določena

Ključne besede: rak (medicina), zdravljenje, interferoni
Objavljeno v DiRROS: 10.01.2024; Ogledov: 79; Prenosov: 26
.pdf Celotno besedilo (302,44 KB)

Presejanje in zgodnje odkrivanje raka
2006, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Objavljeno v DiRROS: 07.12.2023; Ogledov: 154; Prenosov: 44
.pdf Celotno besedilo (15,22 MB)

Odkrivanje in preprečevanje zgodnjih oblik raka debelega črevesa in danke
Borut Štabuc, 2006, ni določena

Ključne besede: črevesje, debelo črevo, danka, rak (medicina), novotvorbe, preprečevanje, diagnostika
Objavljeno v DiRROS: 05.12.2023; Ogledov: 113; Prenosov: 33
.pdf Celotno besedilo (448,58 KB)

Iskanje izvedeno v 0.35 sek.
Na vrh